MedTrace Logo

Clinical Study of Umbilical Cord Blood Mononuclear Cells (UCB-MNCs) in the Treatment of Traumatic Fracture Healing

NCT04997590 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-08-09

No results posted yet for this study

Summary

The aim of this study is to explore the effectiveness and safety of umbilical cord blood mononuclear cells in promoting traumatic fracture healing.

Conditions

  • Bone Nonunion

Interventions

BIOLOGICAL

Umbilical cord blood mononuclear cells

injection of CB-MNCs (cell count 1×108 cells/time) was performed once every 2 week for a total of 3 times.

DRUG

Staphylococcal Enterotoxin C

injection of staphylococcal enterotoxin C was performed once every 2 week for a total of 3 times.

Sponsors & Collaborators

  • Shandong Qilu Stem Cells Engineering Co., Ltd.

    collaborator INDUSTRY

  • Qianfoshan Hospital

    lead OTHER

Principal Investigators

  • Jing Liang, doctor · Qianfoshan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-10
Primary Completion
2021-12-10
Completion
2022-12-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04997590 on ClinicalTrials.gov